20 to 50     : Initial dose of 1.25–2.5 mg once a day. Monitor closely
10 to 20     : Initial dose of 1.25–2.5 mg once a day. Monitor closely
<10           : Initial dose of 1.25–2.5 mg once a day. Use cautiously, with continuous monitoring
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in GFR <10 mL/min
HD                     :Low dialysability. Dose as in GFR <10 mL/min
HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Analgesics: effects enhanced by NSAIDs
Antibacterials: effects enhanced by chloramphenicol, sulphonamides, and trimethoprim; effects possibly enhanced by ciprofloxacin and norfloxacin; effect reduced by rifamycins
Anticoagulants: effect possibly enhanced by coumarins; also possibly changes to INR
Antifungals: concentration increased by fluconazole and miconazole and possibly voriconazoleBosentan: increased risk of hepatoxicity – avoid concomitant use
Ciclosporin: may increase ciclosporin levelsSulfinpyrazone: enhanced effect of sulphonylureas
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
Take with breakfast
OTHER INFORMATION
Metabolites of glibenclamide are only weakly hypoglycaemic; this is not clinically relevant where renal and hepatic functions are normal. If creatinine clearance
<10           : mL/min, accumulation of metabolite and unchanged drug in plasma may cause prolonged hypoglycaemiaCompany information states that use is contraindicated in severe renal impairmentCompensatory excretion via bile in faeces occurs in renal impairment.